van Delft Y - Search Results

1

Lipid profiles for etravirine versus efavirenz in treatment-naive patients in the randomized, double-blind SENSE trial.

Fätkenheuer G, Duvivier C, Rieger A, Durant J, Rey D, Schmidt W, Hill A, van Delft Y, Marks S; SENSE Study Team. Fätkenheuer G, et al. Among authors: van delft y. J Antimicrob Chemother. 2012 Mar;67(3):685-90. doi: 10.1093/jac/dkr533. Epub 2011 Dec 29. J Antimicrob Chemother. 2012. PMID: 22210755 Clinical Trial.

2

96 week results from the MONET trial: a randomized comparison of darunavir/ritonavir with versus without nucleoside analogues, for patients with HIV RNA <50 copies/mL at baseline.

Clumeck N, Rieger A, Banhegyi D, Schmidt W, Hill A, Van Delft Y, Moecklinghoff C, Arribas J. Clumeck N, et al. Among authors: van delft y. J Antimicrob Chemother. 2011 Aug;66(8):1878-85. doi: 10.1093/jac/dkr199. Epub 2011 Jun 7. J Antimicrob Chemother. 2011. PMID: 21652619 Clinical Trial.

3

Sustained HIV RNA suppression after switching from enfuvirtide to etravirine in the early access programme.

Loutfy M, Ribera E, Florence E, De Wit S, Castagna A, Ryan R, Hill A, Vanaken H, van Delft Y, Marks S. Loutfy M, et al. Among authors: van delft y. J Antimicrob Chemother. 2009 Dec;64(6):1341-4. doi: 10.1093/jac/dkp366. Epub 2009 Oct 14. J Antimicrob Chemother. 2009. PMID: 19828488 Clinical Trial. No abstract available.

4

Phase 2 double-blind, randomized trial of etravirine versus efavirenz in treatment-naive patients: 48-week results.

Gazzard B, Duvivier C, Zagler C, Castagna A, Hill A, van Delft Y, Marks S. Gazzard B, et al. Among authors: van delft y. AIDS. 2011 Nov 28;25(18):2249-58. doi: 10.1097/QAD.0b013e32834c4c06. AIDS. 2011. PMID: 21881478 Clinical Trial.

5

Impact of baseline HIV-1 RNA levels on initial highly active antiretroviral therapy outcome: a meta-analysis of 12,370 patients in 21 clinical trials*.

Stephan C, Hill A, Sawyer W, van Delft Y, Moecklinghoff C. Stephan C, et al. Among authors: van delft y. HIV Med. 2013 May;14(5):284-92. doi: 10.1111/hiv.12004. Epub 2012 Nov 22. HIV Med. 2013. PMID: 23171153 Free article. Review.

6

Performance of the Abbott RealTime HIV-1 assay versus the roche amplicor HIV-1 MonitorTM Test, v1.5, UltraSensitive assay for samples with low plasma HIV-1 RNA copy numbers.

Stephan C, Hill A, Hadacek MB, van Delft Y, Moecklinghoff C. Stephan C, et al. Among authors: van delft y. J Antimicrob Chemother. 2014 Jun;69(6):1708-10. doi: 10.1093/jac/dkt538. Epub 2014 Jan 26. J Antimicrob Chemother. 2014. PMID: 24468867 No abstract available.

7

HIV RNA suppression rates after 24 weeks of treatment with etravirine, darunavir/ritonavir and raltegravir in the etravirine early access programme.

Florence E, De Wit S, Castagna A, Ribera E, Hill A, Vanaken H, van Delft Y, Marks S. Florence E, et al. Among authors: van delft y. Int J STD AIDS. 2010 Mar;21(3):224-5. doi: 10.1258/ijsa.2009.009425. Epub 2010 Jan 13. Int J STD AIDS. 2010. PMID: 20071441 Clinical Trial. No abstract available.

8

The MONET trial: week 144 analysis of the efficacy of darunavir/ritonavir (DRV/r) monotherapy versus DRV/r plus two nucleoside reverse transcriptase inhibitors, for patients with viral load < 50 HIV-1 RNA copies/mL at baseline.

Arribas JR, Clumeck N, Nelson M, Hill A, van Delft Y, Moecklinghoff C. Arribas JR, et al. Among authors: van delft y. HIV Med. 2012 Aug;13(7):398-405. doi: 10.1111/j.1468-1293.2012.00989.x. Epub 2012 Mar 14. HIV Med. 2012. PMID: 22413874 Free article. Clinical Trial.

9

Comparison of Roche Amplicor Ultrasensitive and Abbott RealTime assays for samples with low or undetectable HIV RNA levels.

Stephan CJ, Hill A, van Delft Y, Moecklinghoff C. Stephan CJ, et al. Among authors: van delft y. AIDS. 2012 Jul 31;26(12):1580-1. doi: 10.1097/QAD.0b013e3283550dde. AIDS. 2012. PMID: 22810373 No abstract available.

10

Third-line antiretroviral therapy in low-income and middle-income countries (ACTG A5288): a prospective strategy study.

Grinsztejn B, Hughes MD, Ritz J, Salata R, Mugyenyi P, Hogg E, Wieclaw L, Gross R, Godfrey C, Cardoso SW, Bukuru A, Makanga M, Faesen S, Mave V, Wangari Ndege B, Nerette Fontain S, Samaneka W, Secours R, van Schalkwyk M, Mngqibisa R, Mohapi L, Valencia J, Sugandhavesa P, Montalban E, Avihingsanon A, Santos BR, Kumarasamy N, Kanyama C, Schooley RT, Mellors JW, Wallis CL, Collier AC; A5288 Team. Grinsztejn B, et al. Lancet HIV. 2019 Sep;6(9):e588-e600. doi: 10.1016/S2352-3018(19)30146-8. Epub 2019 Jul 29. Lancet HIV. 2019. PMID: 31371262 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

36 results

Search Page